WO2022079001A2 - Sars-cov-2 antigens, diagnostic and therapeutic uses - Google Patents
Sars-cov-2 antigens, diagnostic and therapeutic uses Download PDFInfo
- Publication number
- WO2022079001A2 WO2022079001A2 PCT/EP2021/078138 EP2021078138W WO2022079001A2 WO 2022079001 A2 WO2022079001 A2 WO 2022079001A2 EP 2021078138 W EP2021078138 W EP 2021078138W WO 2022079001 A2 WO2022079001 A2 WO 2022079001A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- subunit
- cov
- sars
- spike protein
- covid
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 23
- 108091007433 antigens Proteins 0.000 title claims abstract description 22
- 102000036639 antigens Human genes 0.000 title claims abstract description 22
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 15
- 208000025721 COVID-19 Diseases 0.000 claims abstract description 53
- 241001678559 COVID-19 virus Species 0.000 claims abstract description 31
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 claims abstract description 12
- 238000011282 treatment Methods 0.000 claims abstract description 11
- 230000000069 prophylactic effect Effects 0.000 claims abstract description 7
- 230000004071 biological effect Effects 0.000 claims abstract description 6
- 230000028993 immune response Effects 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 5
- 238000011321 prophylaxis Methods 0.000 claims abstract description 5
- 101710198474 Spike protein Proteins 0.000 claims description 27
- 229940096437 Protein S Drugs 0.000 claims description 26
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 22
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 19
- 230000000890 antigenic effect Effects 0.000 claims description 15
- 239000012634 fragment Substances 0.000 claims description 15
- 150000007523 nucleic acids Chemical group 0.000 claims description 15
- 229960005486 vaccine Drugs 0.000 claims description 14
- 101800000905 Spike protein S2 Proteins 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 13
- 208000037847 SARS-CoV-2-infection Diseases 0.000 claims description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 8
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 238000001514 detection method Methods 0.000 claims description 8
- 230000003472 neutralizing effect Effects 0.000 claims description 8
- 101500023900 Severe acute respiratory syndrome coronavirus 2 Spike protein S2 Proteins 0.000 claims description 4
- 238000002405 diagnostic procedure Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 108091006367 SARS-CoV-2 Spike Subunit S2 Proteins 0.000 claims description 3
- 238000009007 Diagnostic Kit Methods 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 238000003745 diagnosis Methods 0.000 abstract description 2
- 238000012360 testing method Methods 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 12
- 108060003951 Immunoglobulin Proteins 0.000 description 11
- 102000018358 immunoglobulin Human genes 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 8
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 7
- 241000700605 Viruses Species 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 229940072221 immunoglobulins Drugs 0.000 description 7
- 108020004707 nucleic acids Proteins 0.000 description 7
- 102000039446 nucleic acids Human genes 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 230000004927 fusion Effects 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 108091023037 Aptamer Proteins 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 241000494545 Cordyline virus 2 Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 238000012773 Laboratory assay Methods 0.000 description 3
- 241000315672 SARS coronavirus Species 0.000 description 3
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000012004 kinetic exclusion assay Methods 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 2
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 description 2
- 108010032595 Antibody Binding Sites Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 229940022962 COVID-19 vaccine Drugs 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 101710114810 Glycoprotein Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101710141454 Nucleoprotein Proteins 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 108010079855 Peptide Aptamers Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 101710167605 Spike glycoprotein Proteins 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 108020000999 Viral RNA Proteins 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- -1 fatty acid esters Chemical class 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- 210000004779 membrane envelope Anatomy 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 229940055729 papain Drugs 0.000 description 2
- 235000019834 papain Nutrition 0.000 description 2
- AQIXEPGDORPWBJ-UHFFFAOYSA-N pentan-3-ol Chemical compound CCC(O)CC AQIXEPGDORPWBJ-UHFFFAOYSA-N 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000010470 Ageusia Diseases 0.000 description 1
- 206010002653 Anosmia Diseases 0.000 description 1
- 241000750690 Aptus Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 101710139375 Corneodesmosin Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010050685 Cytokine storm Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 101710204837 Envelope small membrane protein Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710145006 Lysis protein Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101710085938 Matrix protein Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 101710127721 Membrane protein Proteins 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000577979 Peromyscus spicilegus Species 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 229940022005 RNA vaccine Drugs 0.000 description 1
- 208000036284 Rhinitis seasonal Diseases 0.000 description 1
- 108091005609 SARS-CoV-2 Spike Subunit S1 Proteins 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 241000008910 Severe acute respiratory syndrome-related coronavirus Species 0.000 description 1
- 101800000904 Spike protein S1 Proteins 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 238000011948 assay development Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 229960001950 benzethonium chloride Drugs 0.000 description 1
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- HUTDDBSSHVOYJR-UHFFFAOYSA-H bis[(2-oxo-1,3,2$l^{5},4$l^{2}-dioxaphosphaplumbetan-2-yl)oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O HUTDDBSSHVOYJR-UHFFFAOYSA-H 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- LRHPLDYGYMQRHN-UHFFFAOYSA-N butyl alcohol Substances CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 206010052015 cytokine release syndrome Diseases 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- 229920001477 hydrophilic polymer Polymers 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- YWXYYJSYQOXTPL-SLPGGIOYSA-N isosorbide mononitrate Chemical compound [O-][N+](=O)O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@@H]21 YWXYYJSYQOXTPL-SLPGGIOYSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Chemical class 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000004001 molecular interaction Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108091008104 nucleic acid aptamers Proteins 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000255 pathogenic effect Toxicity 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001932 seasonal effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000036303 septic shock Effects 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- SFVFIFLLYFPGHH-UHFFFAOYSA-M stearalkonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 SFVFIFLLYFPGHH-UHFFFAOYSA-M 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1002—Coronaviridae
- C07K16/1003—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2 or Covid-19]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
Definitions
- This invention relates to antigens of SARS-CoV-2, diagnostic and therapeutic modalities thereto, and related uses in the diagnosis, prophylactic and therapy of COVID-19.
- Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It was first identified in December 2019 in Wuhan, Hubei, China, and has resulted in an ongoing pandemic. The first confirmed case has been traced back to 17 November 2019 in Hubei. As of 9 July 2020, more than 12.1 million cases have been reported across 188 countries and territories, resulting in more than 552,000 deaths (Guo et al., Frontiers in Cell and Developmental Biology 2020, 8:410).
- SARS-CoV-2 severe acute respiratory syndrome coronavirus 2
- ARDS acute respiratory distress syndrome
- SARS-CoV-2 (GenBank accession number: MN908947, isolate Wuhan-Hu-1) is a strain of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). It is a positivesense single-stranded RNA (+ssRNA) virus, with a single linear viral RNA molecule. Each SARS-CoV-2 virion is 50-200 nanometres in diameter. Like other coronaviruses, SARS- CoV-2 has four structural proteins, known as the S (spike), E (envelope), M (membrane), and N (nucleocapsid) proteins; the N protein is associated with the viral RNA genome, while the S, E, and M proteins together build the viral envelope.
- S spike
- E envelope
- M membrane
- N nucleocapsid
- the spike protein is the protein responsible for allowing the virus to attach to and fuse with the membrane of a host cell; specifically, its SI subunit attaches to the cellular receptor, the S2 subunit facilitates fusion with the cellular membrane fusion (Su et al., Vaccine 2020, 38: 5071-5075; Walls et al., Cell 2020, 180:281-292, Lan et al., Nature 2020, 581 :215-220, Perotta et al., Respiratory Medicine 2020, 168: 105996). It is suggested that the spike protein receptor binding domain (RBD) binds to the receptor angiotensin converting enzyme 2 (ACE2) on human cells.
- ACE2 angiotensin converting enzyme 2
- the spike glycoprotein (in this application, the terms ’’spike glycoprotein” and “spike protein” are used synonymously) of SARS-CoV-2 is a membrane protein of 1273 amino acids (SEQ ID NO: 1, NCBI Reference Sequence: YP_009724390. Iv, isolate Wuhan-Hu- 1).
- the S2 subunit comprises amino acid 662-1270 of the spike protein sequence (SEQ ID NO.: 2).
- Sequence motifs within the S2 subunit comprise a fusion peptide region (FP, SEQ ID NO.: 3), and two heptad repeat regions (HR1, SEQ ID NO: 4, HR2, SEQ ID NO: 5).
- vaccines comprising spike protein, or antigenic sequences thereof, in particular the RBD domain of the SI subunit.
- Proposed or approved vaccines are based on antigenic peptides, viral vectors or nucleic acids capable of expression of antigenic spike protein sequences, or inactivated virus (Ahmed et al, Viruses 2020, 12:254, Kalita et al., Microbial Pathogenesis 2020, 145: 10236, Bhattacharya e al., J Med Virol. 2020, 92:618-631, Smith et al., Nature Comm.
- the present invention relates to a pharmacologically active compound which either elicits an immune response against the S2 subunit of SARS-CoV-2 spike protein, or neutralizes a biological activity of the S2 subunit of SARS-CoV-2 spike protein, for use in the prophylaxis or treatment of COVID-19.
- the present invention relates to a method of prophylactic or therapeutic treatment of an individual being at risk of acquiring COVID-19, or having clinical signs of COVID-19, or having been tested positive for SARS-CoV-2 in a diagnostic test, comprising administering to the individual a therapeutically effective amount of a compound which either elicits an immune response against the S2 subunit of SARS-CoV- 2 spike protein, or neutralizes a biological activity of the S2 subunit of SARS-CoV-2 spike protein.
- the present invention relates to an antibody which is specific for SARS- CoV-2 spike protein S2 subunit, but does not bind to the SI subunit, for use in the prophylaxis or treatment of COVID-19.
- the antibody is a neutralizing antibody.
- the antibody binds to an epitope within SEQ ID NO.: 2.
- the present invention relates to a vaccine against SARS-CoV-2 infection, comprising one or more antigenic peptides of spike protein S2 subunit, or a nucleic acid sequence coding for one or more antigenic peptides of spike protein S2 subunit, but no peptides of spike protein SI subunit, or respective nucleic acid sequence.
- the present invention relates to a vaccine against SARS-CoV-2 infection, comprising one or more antigenic peptides of spike protein S2 subunit, or a nucleic acid sequence coding for one or more antigenic peptides of spike protein S2 subunit, and peptides of spike protein SI subunit, or respective nucleic acid sequence.
- the present invention relates to diagnostic kit for the determination of the level of antibodies specific for SARS-CoV-2 spike protein S2 subunit in a sample, comprising a. isolated SARS-CoV-2 S2 subunit antigen, or fragment thereof b. means for detection whether antibodies from that sample have bound to said S2 subunit antigen.
- the present invention relates to process for deciding on a therapeutic intervention for a patient suspected or known to be infected by SARS-CoV-2, with the steps a. Obtaining either a blood sample or a saliva sample or a tear fluid sample from said patient; b. Determining the level of antibodies against spike protein SI subunit and the level of antibodies against spike protein S2 subunit in said sample; and c. Deciding on the therapeutic intervention based on the results obtained in step.
- Figure 1 Detectability of SARS-CoV-2 RNA and different antibodies against SARS- CoV-2 at different stages during the course of an infection and interpretation of combined diagnostic test results. This graphic is for illustrative purposes only and does not represent actual levels of RNA/each antibody.
- COVID-19ip COVID-19 history unknown before program but identified as positive during the program
- COVID-19kp positive COVID-19 history known before program
- COVID-19neg COVID-19 history unknown before program and not identified during the program.
- FIG. 1 IgG against SI protein (Eurolmmun) over time.
- COVID-19ip COVID-19 history unknown before program but identified as positive during the program
- COVID-19kp positive COVID-19 history known before program
- COVID-19neg COVID-19 history unknown before program and not identified during the program.
- FIG. 1 IgG against S1/S2 proteins (Diasorin CLIA) over time.
- COVID-19ip COVID-19 history unknown before program but identified as positive during the program
- COVID-19kp positive COVID-19 history known before program
- COVID-19neg COVID-19 history unknown before program and not identified during the program.
- the present invention is based on the observation that a high S2 subunit specific IgG antibody titer after SARS-CoV-2 infection correlates with a mild or even subclinical course of the infection, or disease. On the other hand, a more severe course of the disease may be associated with high titer of SI subunit specific IgG antibodies.
- the present invention is based on the observation that S2 subunit specific IgG antibody titer increase in the course of healing COVID-19, whereas SI subunit specific IgG antibody titer may decrease rapidly.
- the present invention relates to the S2 subunit of SARS-CoV-2 spike protein as a target for therapeutic intervention, and as source of antigen for an anti-SARS-CoV-2 vaccine.
- said S2 subunit comprises the amino acid sequence as represented in SEQ ID NO.: 2.
- said S2 subunit consists of the amino acid sequence as represented in SEQ ID NO.: 2. It is understood that virus strains evolve over time and acquire mutations (substitutions, insertions, deletions). Hence, the amino acid sequence of the S2 subunit may differ from SEQ ID No.: 2 by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more residues.
- the present invention relates to an antibody having specificity for the S2 subunit of the spike protein of SARS-CoV-2, for use in medicine.
- the present invention relates to an antibody having specificity for the S2 subunit of the spike protein of SARS-CoV-2, for use in the prophylactic or therapeutic treatment of COVID-19.
- the epitope for the antibody is within SEQ ID NO.: 2, or a sequence which differs by 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids from SEQ ID NO.: 2.
- “Having specificity”, or “specific for” in the context of the present invention means having a high binding affinity for the S2 subunit of the spike protein of SARS-CoV-2, but low or no measurable binding affinity to unrelated targets, for example human proteins.
- antibodies specific for the S2 subunit of the spike protein in the context of the present invention must not bind, or bind only with very low affinity (Ko>100pM, see below) to isolated SI subunit, or discrete epitopes within the SI subunit of the spike protein. In other words, such antibodies shall discriminate between the SI and S2 subunits of the spike protein of SARS-CoV-2.
- S2 specific antibodies in the context of the present invention may cross-react with S2 subunits of spike proteins of closely related corona virus strains.
- the S2 subunit is highly conserved between SARS-CoV- 2 and SARS-CoV-1 that caused an outbreak in 2002/2003, and antibodies specific for the S2 subunit of the SARS-CoV-1 spike protein have been shown to be cross-reactive to SARS-CoV-2 (Zheng et al., Eurosurveillance 2020, 25(28): 19-28, Lv et al., Cell Reports 2020, 31(9): 1-6). Antibodies showing this type of cross-reactivity are therefore within the ambit of the present invention.
- the antibody binds to the S2 subunit of the spike protein of SARS-.CoV-2 with an affinity, as determined e.g. by surface plasmon resonance analysis (Malmqvist M., "Surface plasmon resonance for detection and measurement of antibody-antigen affinity and kinetics.”, Curr Opin Immunol. 1993 Apr;5(2):282-6.), with a KD value ranging from 1 pM to 100 pM, preferably 1 pM to 1 pM.
- Antibody affinity can also be measured using kinetic exclusion assay (KinExA) technology (Darling, R.J., and Brault P-A., “Kinetic exclusion assay technology: Characterization of Molecular Interactions.” ASSAY and Drug Development Technologies. 2004, Dec 2(6): 647-657).
- KinExA kinetic exclusion assay
- Antibodies and methods of generating antibodies against defined antigens are well-known in the art.
- Antibodies also known as immunoglobulins, abbreviated Ig
- Ig immunoglobulins
- They are typically made of basic structural units - each with two large heavy chains and two small light chains - to form, for example, monomers with one unit, dimers with two units or pentamers with five units
- the basic unit is a heterotetrameric glycoprotein, typically of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains.
- Each light chain is covalently linked to a heavy chain by one disulfide bond to form a heterodimer, and the heterotrimeric molecule is formed through a covalent disulfide linkage between the two identical heavy chains of the heterodimers.
- the light and heavy chains are linked together by one disulfide bond, the number of disulfide linkages between the two heavy chains varies by immunoglobulin isotype.
- Each heavy and light chain also has regularly spaced intrachain disulfide bridges.
- VL variable light chain
- CL carboxy-terminal constant domain
- the VL domain associates non-covalently with the VH domain, whereas the CL domain is commonly covalently linked to the CHI domain via a disulfide bond. Particular amino acid residues are believed to form an interface between the light and heavy chain variable domains.
- Antibodies can bind, by non-covalent interaction, to other molecules or structures known as antigens. This binding is specific in the sense that an antibody will only bind to a specific structure with high affinity. The unique part of the antigen recognized by an antibody is called an epitope, or antigenic determinant.
- variable domain The part of the antibody binding to the epitope is sometimes called paratope and resides in the so-called variable domain, or variable region (Fv) of the antibody.
- the variable domain comprises three so-called complementary-determining region (CDR’s) spaced apart by framework regions (FR’s).
- CDR CDR
- Chothia and Lesk J. Mol. Biol. 1987, 196: 901-917
- Kabat E.A. Kabat, T.T. Wu, H. Bilofsky, M. Reid-Miller and H. Perry, Sequence of Proteins of Immunological Interest, National Institutes of Health, Bethesda (1983)).
- antibody molecule or “antibody” (used synonymously herein) do not only include antibodies as they may be found in nature, comprising e.g. two light chains and two or heavy chains, or just two heavy chains as in camelid species, but furthermore encompasses all molecules comprising at least one paratope with binding specificity to an antigen and structural similarity to a variable domain of an immunoglobulin.
- an antibody according to the invention may be a polyclonal antibody, a monoclonal antibody, a human antibody, a humanized antibody, a chimeric antibody, a fragment of an antibody, in particular a Fv, Fab, Fab’, or F(ab’)2 fragment, a single chain antibody, in particular a single chain variable fragment (scFv), a domain antibody, a peptide aptamer, a nucleic acid aptamer or a nanobody.
- scFv single chain variable fragment
- Polyclonal antibodies represent a collection of antibody molecules with different amino acid sequences and may be obtained from the blood of vertebrates after immunization with the antigen by processes well-known in the art.
- Monoclonal antibodies are monospecific antibodies that are identical in amino acid sequence. They may be produced by hybridoma technology from a hybrid cell line (called hybridoma) representing a clone of a fusion of a specific antibody -producing B cell with a myeloma (B cell cancer) cell. Alternatively, monoclonal antibodies may be produced by recombinant expression in host cells.
- a “chimeric antibody” is understood to be antibody comprising a sequence part (e.g. a variable domain) derived from one species (e.g. mouse) fused to a sequence part (e.g. the constant domains) derived from a different species (e.g. human).
- a “humanized antibody” is an antibody comprising a variable domain originally derived from a non-human species, wherein certain amino acids have been mutated to make the overall sequence of that variable domain more closely resemble to a sequence of a human variable domain. Methods of chimerisation and humanization of antibodies are well-known in the art.
- Antibody molecules according to the present invention also include fragments of immunoglobulins which retain antigen binding properties, like Fab, Fab’, or F(ab’)2 fragments.
- Such fragments may be obtained by fragmentation of immunoglobulins e.g. by proteolytic digestion, or by recombinant expression of such fragments.
- immunoglobulin digestion can be accomplished by means of routine techniques, e.g. using papain or pepsin.
- Papain digestion of antibodies typically produces two identical antigen binding fragments, so-called Fab fragments, each with a single antigen binding site, and a residual Fc fragment. Pepsin treatment yields an F(ab')2.
- variable domains are each fused to an immunoglobulin constant domain, preferably of human origin.
- the heavy chain variable domain may be fused to a CHI domain (a so-called Fd fragment), and the light chain variable domain may be fused to a CL domain.
- Fab molecules may be produced by recombinant expression of respective nucleic acids in host cells, see below.
- Peptide Aptamers are artificial proteins selected or engineered to bind specific target molecules consisting of one or more peptide loops of variable sequences displayed by a protein scaffold. Aptamers are less immunogenic than antibodies and therefore provoke less undesirable reactions. Molecules like proteins reversibly bound to aptamers allow controlled release of biological molecules. On the other hand the bonds formed by aptamers are usually weak and they are easily digested by enzymes limiting their effectiveness.
- Nucleic acid apatamers (from the Latin aptus - fit, and Greek meros - part) are oligonucleotide or peptide molecules that bind to a specific target molecule.
- variable domains of immunoglobulins or molecules derived from such variable domains, in a different molecular context.
- these antibody molecules are smaller in size compared to immunoglobulins, and may comprise a single amino acid chain or several amino acid chains.
- a single-chain variable fragment scFv
- S serine
- G glycine
- Single domain antibodies or hurrynanobodies” harbour an antigen-binding site in a single Ig-like domain.
- One or more single domain antibodies with binding specificity for the same or a different antigen may be linked together, resulting for example in bispecific antibodies.
- the antibody molecule may be fused (as a fusion protein) or otherwise linked (by covalent or non-covalent bonds) to other molecular entities having a desired impact on the properties of the antibody molecule.
- it may be desirable to improve pharmacokinetic properties of antibody molecules, stability e.g. in body fluids such as blood, in particular in the case of single chain antibodies or domain antibodies.
- a number of technologies have been developed in this regard, in particular to prolong the half-life of such antibody molecules in the circulation, such as pegylation, fusing or otherwise covalently attaching the antibody molecule to another antibody molecule having affinity to a serum protein like albumin, or expression of the antibody molecule as fusion protein with all or part of a serum protein like albumin or transferrin.
- antibodies of the IgG subtype may be well suited.
- IgG subtypes e.g. IgG2 or IgG3, or IgA may be used.
- the antibody is a neutralizing antibody.
- a neutralizing antibody in the context of the present invention is capable, by its binding to the S2 subunit, of partly or completely inhibiting a biological activity of the spike protein and/or its S2 subunit, for example inhibiting or preventing fusion of the viral envelope and cellular membranes. Ideally, by this neutralizing activity, the infection of the cells and the subsequent pathogenic effects of SARS-CoV-2 can be diminished or prevented.
- Whether a given antibody having binding specificity for the S2 subunit of the spike protein has neutralizing activity can be determined by the expert with assay methods known in the art (Hansen et al., Science 2020, 10.1126/science.abd0827, Elshabrawy et al., PLOS One 2010, 7(11): e50366), Lip et al. 2006, J Virol. 80(2):841-950). Methods of manufacturing of an antibody in a quantity and quality that it can be used in medicine are well-known in the art.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an antibody against the S2 subunit of the spike protein and a pharmaceutically acceptable carrier.
- the antibody is included into pharmaceutical compositions appropriate to facilitate administration to animals or humans.
- Typical formulations of the antibody molecule can be prepared by mixing the antibody molecule with physiologically acceptable carriers, excipients or stabilizers, in the form of lyophilized or otherwise dried formulations or aqueous solutions or aqueous or non-aqueous suspensions. Carriers, excipients, modifiers or stabilizers are nontoxic at the dosages and concentrations employed.
- buffer systems such as phosphate, citrate, acetate and other anorganic or organic acids and their salts; antioxidants including ascorbic acid and methionine; preservatives such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone or polyethylene glycol (PEG); amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, oligosaccharides,
- the pharmaceutical composition comprises the antibody in an aqueous, buffered solution at a concentration of 10, 20, 30, 40, or 50 mg/ml, or a lyophilisate made from such a solution.
- the antibody is administered by any suitable means, including, parenteral, subcutaneous, intraperitoneal, intrapulmonary, and intranasal.
- Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration.
- the appropriate dosage of antibody will depend on a variety of factors such as the type of disease to be treated, as defined above, the severity and course of the disease, whether the antibody is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody, and the discretion of the attending physician.
- the antibody is suitably administered to the patient at one time or over a series of treatments.
- the present invention relates to a vaccine against SARS-CoV-2 infection, comprising one or more antigenic peptides of spike protein S2 subunit, but no peptides of spike protein S 1 subunit.
- Such vaccines could comprise recombinantly produced S2 subunit protein of SEQ ID NO.: 2, or one or more fragments thereof.
- the present invention relates to a vaccine against SARS-CoV-2 infection, comprising one or more nucleic acids encoding antigenic peptides of spike protein S2 subunit, but no nucleic acids encoding peptides of spike protein SI subunit.
- Doremalen et al., bioRxiv 2020.05.13.093195 describe production and testing of a COVID-19 vaccine based on an adenoviral vector (ChAdOxl nCov-19) that comprises a nucleic acid encoding amino acids 2-1273 of SARS-CoV-2 spike protein, i.e. including both SI and S2 subunits.
- adenoviral vector ChoAdOxl nCov-19
- One mode of carrying out the present invention would be to replace the spike sequence used by Doremalen by a shorter sequence comprising S2 epitopes only, e.g. amino acids 662-1273, or fragment thereof, like SEQ ID NO.: 2.
- a different way of carrying out the present invention is the production of an RNA-based vaccine as described in Mulligan et al.
- a throat swab was collected by qualified healthcare personnel. Samples were assayed using the Kylt® SARS-CoV-2 Initial Screening/Confirmation (AniCon Labor GmbH, Holtinghausen, Germany). Confirmatory RT-PCR for positive initial RT-PCR results and IgM- (LFA) and IgA- (ELISA) positive participants were performed by an independent laboratory.
- LFAs for IgM and IgG determination were used using fingertip blood or venous blood samples.
- the following test systems were evaluated: VivaDiag COVID-19 IgM/IgG Rapid Test (VivaChek Biotech Co Ltd, Hangzhou, China); 2019-nCoV IgG/IgM Rapid Test Cassette (MoLab GmbH, Langenfeld, Germany); SARS-CoV-2 rapid IgM/IgG antibody test (Nano Repro AG, Marburg, Germany); and PerGrande SARS-CoV-2 Antibody Detection Kit IgG (PerGrande BioTech Development Co Ltd, Beijing, China); all directed against the N protein of the virus.
- Test results and demographic data were analyzed using descriptive statistics. Standard statistical parameters of the test performance, like sensitivity, specificity and positive and negative predictive values, were calculated. To that end, medical judgment and a post hoc classification of each participant’s Covid- 19 history — based on the full diagnostic information package accumulated during the testing program — was considered as gold standard. The (semi-)quantitative outcomes from the laboratory assay tests were plotted over time and evaluated by linear regression to quantify the dynamics of potential seroconversion. RESULTS
- Participants from the COVID- 19kp or COVID-lOip groups were numerically less likely to report allergies compared with the COVID- 19neg group, including the most commonly reported allergy ‘allergic rhinitis due to pollen’, less likely to take antihistamines, to have baseline IgE values of >100 lU/mL and less likely to have had an influenza vaccination in 2019/2020 (Table 1 and Supplementary Figure S3).
- the Diasorin CLIA which detects IgG against both S 1 and S2, showed a sustained IgG response over time (Figure 4A) in the COVID-19kp group.
- Figure 4B the observed immune response against S1/S2 remained stable and persistent, although notably below the COVID- 19kp group; however, the signal remained sufficiently large for a positive detection ( Figure 4C).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
This invention relates to antigens of SARS-CoV-2, diagnostic and therapeutic modalities thereto, and related uses in the diagnosis, prophylactic and therapy of COVID-19. In particular, the present invention relates to a pharmacologically active compound which either elicits an immune response against the S2 subunit of SARS-CoV-2 spike protein, or neutralizes a biological activity of the S2 subunit of SARS-CoV-2 spike protein, for use in the prophylaxis or treatment of COVID-19.
Description
SARS-COV-2 ANTIGENS, DIAGNOSTIC AND THERAPEUTIC USES
BACKGROUND OF THE INVENTION
TECHNICAL FIELD
This invention relates to antigens of SARS-CoV-2, diagnostic and therapeutic modalities thereto, and related uses in the diagnosis, prophylactic and therapy of COVID-19.
BACKGROUND INFORMATION
Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It was first identified in December 2019 in Wuhan, Hubei, China, and has resulted in an ongoing pandemic. The first confirmed case has been traced back to 17 November 2019 in Hubei. As of 9 July 2020, more than 12.1 million cases have been reported across 188 countries and territories, resulting in more than 552,000 deaths (Guo et al., Frontiers in Cell and Developmental Biology 2020, 8:410).
Common symptoms include fever, cough, fatigue, shortness of breath, and loss of smell and taste. While the majority of cases result in mild symptoms, some progress to acute respiratory distress syndrome (ARDS) possibly precipitated by cytokine storm, multi-organ failure, septic shock, and blood clots. The time from exposure to onset of symptoms is typically around five days, but may range from two to fourteen days.
SARS-CoV-2 (GenBank accession number: MN908947, isolate Wuhan-Hu-1) is a strain of severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2). It is a positivesense single-stranded RNA (+ssRNA) virus, with a single linear viral RNA molecule. Each SARS-CoV-2 virion is 50-200 nanometres in diameter. Like other coronaviruses, SARS- CoV-2 has four structural proteins, known as the S (spike), E (envelope), M (membrane), and N (nucleocapsid) proteins; the N protein is associated with the viral RNA genome, while the S, E, and M proteins together build the viral envelope. The spike protein is the protein responsible for allowing the virus to attach to and fuse with the membrane of a host cell; specifically, its SI subunit attaches to the cellular receptor, the S2 subunit facilitates fusion with the cellular membrane fusion (Su et al., Vaccine 2020, 38: 5071-5075; Walls et
al., Cell 2020, 180:281-292, Lan et al., Nature 2020, 581 :215-220, Perotta et al., Respiratory Medicine 2020, 168: 105996). It is suggested that the spike protein receptor binding domain (RBD) binds to the receptor angiotensin converting enzyme 2 (ACE2) on human cells.
The spike glycoprotein (in this application, the terms ’’spike glycoprotein” and “spike protein” are used synonymously) of SARS-CoV-2 is a membrane protein of 1273 amino acids (SEQ ID NO: 1, NCBI Reference Sequence: YP_009724390. Iv, isolate Wuhan-Hu- 1). The S2 subunit comprises amino acid 662-1270 of the spike protein sequence (SEQ ID NO.: 2). Sequence motifs within the S2 subunit comprise a fusion peptide region (FP, SEQ ID NO.: 3), and two heptad repeat regions (HR1, SEQ ID NO: 4, HR2, SEQ ID NO: 5).
Efforts to find prophylactic or therapeutic modalities for COVID-19, as well as improved diagnostic methods, are underway.
As one therapeutic option, the use of neutralizing antibodies targeting e.g. the spike protein or its subunits have been suggested, with a focus on antibodies targeting the RBD domain of the SI subunit (Ho M, Antibody Ther. 2020, 3(2): 109-114; Hansen et al., Science 2020, 10.1126/science.abd0827, Rogers et al., Science 2020, 10.1126/science.abc7520, .Elshabrawy, Vaccines 2020, 8:335, Jiang et al., Trends Immunol. 2020, 41(5): 355-359, Wang et al., Nature Communications 2020, 11 :2251).
Different approaches for vaccination have been suggested and some have been developed and approved by regulatory authorities. Also here, there is strong emphasis on vaccines comprising spike protein, or antigenic sequences thereof, in particular the RBD domain of the SI subunit. Proposed or approved vaccines are based on antigenic peptides, viral vectors or nucleic acids capable of expression of antigenic spike protein sequences, or inactivated virus (Ahmed et al, Viruses 2020, 12:254, Kalita et al., Microbial Pathogenesis 2020, 145: 10236, Bhattacharya e al., J Med Virol. 2020, 92:618-631, Smith et al., Nature Comm. 2020, 11 :2601; Zhu et al., Lancet 2020, 395: 1845-1854, Salvatori et al. J Transl Med (2020), 18:222, Wang et al., Med Sci Monit. 2020, 26:e924700, Doremalen et al., bioRxiv 2020.05.13.093195; Mulligan et al., medRxiv 2020.06.30.20142570, Jackson et al., New Engl J Med 2020, DOI: 10.1056/NEJMoa2022483).
Neutralizing human monoclonal antibodies against highly conserved HR1 and HR2 domains of the spike protein S2 subunit, as well as vaccines comprising respective antigen, had been previously suggested as either therapeutic agents or prophylactic measures, respectively, against infection with related SARS-CoV-1 strain that led to an epidemic in 2002/2003 (Elshabrawy et al., PLOS One 2010, 7(11): e50366, Lip et al. 2006, J Virol. 80(2):841-950).
Immunoassays have been used to profile antibody responses post SARS-CoV-2 infection (Nisreen MAO et al., EID Journal 2020, 26(7): 1478-1488; Lee CY et al., Front. Immunol. 2020, 11 :879)
BRIEF SUMMARY OF THE INVENTION
In one aspect, the present invention relates to a pharmacologically active compound which either elicits an immune response against the S2 subunit of SARS-CoV-2 spike protein, or neutralizes a biological activity of the S2 subunit of SARS-CoV-2 spike protein, for use in the prophylaxis or treatment of COVID-19.
In another aspect, the present invention relates to a method of prophylactic or therapeutic treatment of an individual being at risk of acquiring COVID-19, or having clinical signs of COVID-19, or having been tested positive for SARS-CoV-2 in a diagnostic test, comprising administering to the individual a therapeutically effective amount of a compound which either elicits an immune response against the S2 subunit of SARS-CoV- 2 spike protein, or neutralizes a biological activity of the S2 subunit of SARS-CoV-2 spike protein.
In another aspect, the present invention relates to an antibody which is specific for SARS- CoV-2 spike protein S2 subunit, but does not bind to the SI subunit, for use in the prophylaxis or treatment of COVID-19. Preferably, the antibody is a neutralizing antibody. Preferably, the antibody binds to an epitope within SEQ ID NO.: 2.
In another aspect, the present invention relates to a vaccine against SARS-CoV-2 infection, comprising one or more antigenic peptides of spike protein S2 subunit, or a nucleic acid sequence coding for one or more antigenic peptides of spike protein S2 subunit, but no peptides of spike protein SI subunit, or respective nucleic acid sequence.
In another aspect, the present invention relates to a vaccine against SARS-CoV-2 infection, comprising one or more antigenic peptides of spike protein S2 subunit, or a nucleic acid sequence coding for one or more antigenic peptides of spike protein S2 subunit, and peptides of spike protein SI subunit, or respective nucleic acid sequence.
In another aspect, the present invention relates to diagnostic kit for the determination of the level of antibodies specific for SARS-CoV-2 spike protein S2 subunit in a sample, comprising a. isolated SARS-CoV-2 S2 subunit antigen, or fragment thereof b. means for detection whether antibodies from that sample have bound to said S2 subunit antigen.
In another aspect, the present invention relates to process for deciding on a therapeutic intervention for a patient suspected or known to be infected by SARS-CoV-2, with the steps a. Obtaining either a blood sample or a saliva sample or a tear fluid sample from said patient; b. Determining the level of antibodies against spike protein SI subunit and the level of antibodies against spike protein S2 subunit in said sample; and c. Deciding on the therapeutic intervention based on the results obtained in step.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1. Detectability of SARS-CoV-2 RNA and different antibodies against SARS- CoV-2 at different stages during the course of an infection and interpretation of combined diagnostic test results. This graphic is for illustrative purposes only and does not represent actual levels of RNA/each antibody.
Figure 2. IgA against SI protein (Eurolmmun) over time. Panel A. Participants with COVID-19 history known before the program start (n=20); B. Participants with COVID-19 history identified during the program (n=10); C. Comparison of levels in all participants (n=141) over all four visits.
*An optical density [OD] ratio of serum sample/OD of calibrator below 0.8 was evaluated as negative, 0.8— <1.1 as borderline and >1.1 as positive. COVID-19ip: COVID-19 history unknown before program but identified as positive during the program; COVID-19kp: positive COVID-19 history known before program; COVID-19neg: COVID-19 history unknown before program and not identified during the program.
Figure 3. IgG against SI protein (Eurolmmun) over time. Panel A. Participants with COVID-19 history known before the program (n=20); B. Participants with COVID-19 history identified during the program (n=10); C. Comparison of levels in all participants (n=141) over all four visits.
*An optical density [OD] ratio of serum sample/OD of calibrator below 0.8 was evaluated as negative, 0.8-< 1.1 as borderline and >1.1 as positive. COVID-19ip: COVID-19 history unknown before program but identified as positive during the program; COVID-19kp: positive COVID-19 history known before program; COVID-19neg: COVID-19 history unknown before program and not identified during the program.
Figure 4. IgG against S1/S2 proteins (Diasorin CLIA) over time. Panel A. Participants with COVID-19 history known before the program start (n=20); B. Participants with COVID-19 history unknown before the program but identified during the program (n=10); C. Comparison of levels in all participants (n=141) over all four visits.
* A level of <12 IU was considered negative; 12— <15 as borderline and >15 as positive. COVID-19ip: COVID-19 history unknown before program but identified as positive during the program; COVID-19kp: positive COVID-19 history known before program; COVID-19neg: COVID-19 history unknown before program and not identified during the program.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is based on the observation that a high S2 subunit specific IgG antibody titer after SARS-CoV-2 infection correlates with a mild or even subclinical course of the infection, or disease. On the other hand, a more severe course of the disease may be associated with high titer of SI subunit specific IgG antibodies. In another aspect, the present invention is based on the observation that S2 subunit specific IgG antibody titer increase in the course of healing COVID-19, whereas SI subunit specific IgG antibody titer may decrease rapidly.
The present invention relates to the S2 subunit of SARS-CoV-2 spike protein as a target for therapeutic intervention, and as source of antigen for an anti-SARS-CoV-2 vaccine. In a preferred embodiment, said S2 subunit comprises the amino acid sequence as represented in SEQ ID NO.: 2. In another embodiment, said S2 subunit consists of the amino acid sequence as represented in SEQ ID NO.: 2. It is understood that virus strains evolve over time and acquire mutations (substitutions, insertions, deletions). Hence, the amino acid sequence of the S2 subunit may differ from SEQ ID No.: 2 by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more residues.
In one embodiment, the present invention relates to an antibody having specificity for the S2 subunit of the spike protein of SARS-CoV-2, for use in medicine. In particular, the present invention relates to an antibody having specificity for the S2 subunit of the spike protein of SARS-CoV-2, for use in the prophylactic or therapeutic treatment of COVID-19. Preferably, the epitope for the antibody is within SEQ ID NO.: 2, or a sequence which differs by 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acids from SEQ ID NO.: 2.
“Having specificity”, or “specific for” in the context of the present invention means having a high binding affinity for the S2 subunit of the spike protein of SARS-CoV-2, but low or no measurable binding affinity to unrelated targets, for example human proteins. Importantly, antibodies specific for the S2 subunit of the spike protein in the context of the present invention must not bind, or bind only with very low affinity (Ko>100pM, see below) to isolated SI subunit, or discrete epitopes within the SI subunit of the spike protein. In other words, such antibodies shall discriminate between the SI and S2 subunits
of the spike protein of SARS-CoV-2. Still, S2 specific antibodies in the context of the present invention may cross-react with S2 subunits of spike proteins of closely related corona virus strains. For example, the S2 subunit is highly conserved between SARS-CoV- 2 and SARS-CoV-1 that caused an outbreak in 2002/2003, and antibodies specific for the S2 subunit of the SARS-CoV-1 spike protein have been shown to be cross-reactive to SARS-CoV-2 (Zheng et al., Eurosurveillance 2020, 25(28): 19-28, Lv et al., Cell Reports 2020, 31(9): 1-6). Antibodies showing this type of cross-reactivity are therefore within the ambit of the present invention.
Affinity is the interaction between a single antigen-binding site on an antibody molecule and a single epitope. It is expressed by the association constant KA kass/kdiss, or the dissociation constant KD = kdiss/kass .
In one aspect , the antibody binds to the S2 subunit of the spike protein of SARS-.CoV-2 with an affinity, as determined e.g. by surface plasmon resonance analysis (Malmqvist M., "Surface plasmon resonance for detection and measurement of antibody-antigen affinity and kinetics.", Curr Opin Immunol. 1993 Apr;5(2):282-6.), with a KD value ranging from 1 pM to 100 pM, preferably 1 pM to 1 pM. Antibody affinity can also be measured using kinetic exclusion assay (KinExA) technology (Darling, R.J., and Brault P-A., “Kinetic exclusion assay technology: Characterization of Molecular Interactions.” ASSAY and Drug Development Technologies. 2004, Dec 2(6): 647-657).
Antibodies and methods of generating antibodies against defined antigens are well-known in the art. Antibodies (also known as immunoglobulins, abbreviated Ig) are gamma globulin proteins that can be found in blood or other bodily fluids of vertebrates, and are used by the immune system to identify and neutralize foreign objects, such as bacteria and viruses. They are typically made of basic structural units - each with two large heavy chains and two small light chains - to form, for example, monomers with one unit, dimers with two units or pentamers with five units The basic unit is a heterotetrameric glycoprotein, typically of about 150,000 daltons, composed of two identical light (L) chains and two identical heavy (H) chains. Each light chain is covalently linked to a heavy chain by one disulfide bond to form a heterodimer, and the heterotrimeric molecule is formed through a covalent disulfide linkage between the two identical heavy chains of the
heterodimers. Although the light and heavy chains are linked together by one disulfide bond, the number of disulfide linkages between the two heavy chains varies by immunoglobulin isotype. Each heavy and light chain also has regularly spaced intrachain disulfide bridges. Each heavy chain has at the amino-terminus a variable domain (VH = variable heavy chain), followed by three or four constant domains (CHI, CH2, CH3, and CH4), as well as a hinge region between CHI and Cm. Each light chain has two domains, an amino-terminal variable domain (VL = variable light chain) and a carboxy-terminal constant domain (CL). The VL domain associates non-covalently with the VH domain, whereas the CL domain is commonly covalently linked to the CHI domain via a disulfide bond. Particular amino acid residues are believed to form an interface between the light and heavy chain variable domains. Antibodies can bind, by non-covalent interaction, to other molecules or structures known as antigens. This binding is specific in the sense that an antibody will only bind to a specific structure with high affinity. The unique part of the antigen recognized by an antibody is called an epitope, or antigenic determinant. The part of the antibody binding to the epitope is sometimes called paratope and resides in the so- called variable domain, or variable region (Fv) of the antibody. The variable domain comprises three so-called complementary-determining region (CDR’s) spaced apart by framework regions (FR’s).
Within the context of this invention, reference to CDR’s is based on the definition of Chothia (Chothia and Lesk, J. Mol. Biol. 1987, 196: 901-917), together with Kabat ( E.A. Kabat, T.T. Wu, H. Bilofsky, M. Reid-Miller and H. Perry, Sequence of Proteins of Immunological Interest, National Institutes of Health, Bethesda (1983)).
The art has further developed antibodies and made them versatile tools in medicine and technology. Thus, in the context of the present invention the terms “antibody molecule” or “antibody” (used synonymously herein) do not only include antibodies as they may be found in nature, comprising e.g. two light chains and two or heavy chains, or just two heavy chains as in camelid species, but furthermore encompasses all molecules comprising at least one paratope with binding specificity to an antigen and structural similarity to a variable domain of an immunoglobulin.
Thus, an antibody according to the invention may be a polyclonal antibody, a monoclonal antibody, a human antibody, a humanized antibody, a chimeric antibody, a fragment of an antibody, in particular a Fv, Fab, Fab’, or F(ab’)2 fragment, a single chain antibody, in particular a single chain variable fragment (scFv), a domain antibody, a peptide aptamer, a nucleic acid aptamer or a nanobody.
Polyclonal antibodies represent a collection of antibody molecules with different amino acid sequences and may be obtained from the blood of vertebrates after immunization with the antigen by processes well-known in the art.
Monoclonal antibodies (mAb) are monospecific antibodies that are identical in amino acid sequence. They may be produced by hybridoma technology from a hybrid cell line (called hybridoma) representing a clone of a fusion of a specific antibody -producing B cell with a myeloma (B cell cancer) cell. Alternatively, monoclonal antibodies may be produced by recombinant expression in host cells.
For application in man, it is often desirable to reduce immunogenicity of antibodies originally derived from other species, like mouse. This can be done by construction of chimeric antibodies, or by a process called “humanization”. In this context, a “chimeric antibody” is understood to be antibody comprising a sequence part (e.g. a variable domain) derived from one species (e.g. mouse) fused to a sequence part (e.g. the constant domains) derived from a different species (e.g. human). A “humanized antibody” is an antibody comprising a variable domain originally derived from a non-human species, wherein certain amino acids have been mutated to make the overall sequence of that variable domain more closely resemble to a sequence of a human variable domain. Methods of chimerisation and humanization of antibodies are well-known in the art.
Furthermore, technologies have been developed for creating antibodies based on sequences derived from the human genome, for example by phage display or use of transgenic animals. Such antibodies are “human antibodies” in the context of the present invention.
Antibody molecules according to the present invention also include fragments of immunoglobulins which retain antigen binding properties, like Fab, Fab’, or F(ab’)2
fragments. Such fragments may be obtained by fragmentation of immunoglobulins e.g. by proteolytic digestion, or by recombinant expression of such fragments. For example, immunoglobulin digestion can be accomplished by means of routine techniques, e.g. using papain or pepsin. Papain digestion of antibodies typically produces two identical antigen binding fragments, so-called Fab fragments, each with a single antigen binding site, and a residual Fc fragment. Pepsin treatment yields an F(ab')2. In Fab molecules, the variable domains are each fused to an immunoglobulin constant domain, preferably of human origin. Thus, the heavy chain variable domain may be fused to a CHI domain (a so-called Fd fragment), and the light chain variable domain may be fused to a CL domain. Fab molecules may be produced by recombinant expression of respective nucleic acids in host cells, see below.
Peptide Aptamers are artificial proteins selected or engineered to bind specific target molecules consisting of one or more peptide loops of variable sequences displayed by a protein scaffold. Aptamers are less immunogenic than antibodies and therefore provoke less undesirable reactions. Molecules like proteins reversibly bound to aptamers allow controlled release of biological molecules. On the other hand the bonds formed by aptamers are usually weak and they are easily digested by enzymes limiting their effectiveness.
Nucleic acid apatamers (from the Latin aptus - fit, and Greek meros - part) are oligonucleotide or peptide molecules that bind to a specific target molecule.
A number of technologies have been developed for placing variable domains of immunoglobulins, or molecules derived from such variable domains, in a different molecular context. Those should be also considered as “antibodies” in accordance with the present invention. In general, these antibody molecules are smaller in size compared to immunoglobulins, and may comprise a single amino acid chain or several amino acid chains. For example, a single-chain variable fragment (scFv) is a fusion of the variable regions of the heavy and light chains of immunoglobulins, linked together with a short linker, usually serine (S) or glycine (G). “Single domain antibodies” or „nanobodies” harbour an antigen-binding site in a single Ig-like domain. One or more single domain
antibodies with binding specificity for the same or a different antigen may be linked together, resulting for example in bispecific antibodies.
The antibody molecule may be fused (as a fusion protein) or otherwise linked (by covalent or non-covalent bonds) to other molecular entities having a desired impact on the properties of the antibody molecule. For example, it may be desirable to improve pharmacokinetic properties of antibody molecules, stability e.g. in body fluids such as blood, in particular in the case of single chain antibodies or domain antibodies. A number of technologies have been developed in this regard, in particular to prolong the half-life of such antibody molecules in the circulation, such as pegylation, fusing or otherwise covalently attaching the antibody molecule to another antibody molecule having affinity to a serum protein like albumin, or expression of the antibody molecule as fusion protein with all or part of a serum protein like albumin or transferrin.
For the present invention, antibodies of the IgG subtype, e.g. IgGl, or IgG4, may be well suited. Alternatively, other IgG subtypes, e.g. IgG2 or IgG3, or IgA may be used.
Generation of antibodies having specificity for the S2 subunit of SARS-CoV-2 have been described in the prior art (Zheng et al., Eurosurveillance 2020, 25(28): 19-28, Lip et al. 2006, J Virol. 80(2):841-950).
In a preferred aspect of the invention, the antibody is a neutralizing antibody. A neutralizing antibody in the context of the present invention is capable, by its binding to the S2 subunit, of partly or completely inhibiting a biological activity of the spike protein and/or its S2 subunit, for example inhibiting or preventing fusion of the viral envelope and cellular membranes. Ideally, by this neutralizing activity, the infection of the cells and the subsequent pathogenic effects of SARS-CoV-2 can be diminished or prevented. Whether a given antibody having binding specificity for the S2 subunit of the spike protein has neutralizing activity can be determined by the expert with assay methods known in the art (Hansen et al., Science 2020, 10.1126/science.abd0827, Elshabrawy et al., PLOS One 2010, 7(11): e50366), Lip et al. 2006, J Virol. 80(2):841-950).
Methods of manufacturing of an antibody in a quantity and quality that it can be used in medicine are well-known in the art.
In another aspect, the present invention provides a pharmaceutical composition comprising an antibody against the S2 subunit of the spike protein and a pharmaceutically acceptable carrier.
To be used in medicine, the antibody is included into pharmaceutical compositions appropriate to facilitate administration to animals or humans. Typical formulations of the antibody molecule can be prepared by mixing the antibody molecule with physiologically acceptable carriers, excipients or stabilizers, in the form of lyophilized or otherwise dried formulations or aqueous solutions or aqueous or non-aqueous suspensions. Carriers, excipients, modifiers or stabilizers are nontoxic at the dosages and concentrations employed. They include buffer systems such as phosphate, citrate, acetate and other anorganic or organic acids and their salts; antioxidants including ascorbic acid and methionine; preservatives such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone or polyethylene glycol (PEG); amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, oligosaccharides or polysaccharides and other carbohydrates including glucose, mannose, sucrose, trehalose, dextrins or dextrans; chelating agents such as EDTA; sugar alcohols such as, mannitol or sorbitol; salt-forming counter-ions such as sodium; metal complexes (e.g., Zn-protein complexes); and/or ionic or non-ionic surfactants such as TWEEN™ (polysorbates), PLURONICS™ or fatty acid esters, fatty acid ethers or sugar esters. Also organic solvents can be contained in the antibody formulation such as ethanol or isopropanol. The excipients may also have a release-modifying or absorption-modifying function.
In one aspect, the pharmaceutical composition comprises the antibody in an aqueous, buffered solution at a concentration of 10, 20, 30, 40, or 50 mg/ml, or a lyophilisate made from such a solution.
The antibody is administered by any suitable means, including, parenteral, subcutaneous, intraperitoneal, intrapulmonary, and intranasal. Parenteral infusions include intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration.
For the prevention or treatment of disease, the appropriate dosage of antibody will depend on a variety of factors such as the type of disease to be treated, as defined above, the severity and course of the disease, whether the antibody is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody, and the discretion of the attending physician. The antibody is suitably administered to the patient at one time or over a series of treatments.
In another aspect, the present invention relates to a vaccine against SARS-CoV-2 infection, comprising one or more antigenic peptides of spike protein S2 subunit, but no peptides of spike protein S 1 subunit.
Methods of producing vaccines comprising peptides as antigens are known in the art. Such vaccines could comprise recombinantly produced S2 subunit protein of SEQ ID NO.: 2, or one or more fragments thereof.
In another aspect, the present invention relates to a vaccine against SARS-CoV-2 infection, comprising one or more nucleic acids encoding antigenic peptides of spike protein S2 subunit, but no nucleic acids encoding peptides of spike protein SI subunit.
Methods of producing vaccines comprising nucleic acids encoding antigenic peptides are known in the art.
For example, Doremalen et al., bioRxiv 2020.05.13.093195, describe production and testing of a COVID-19 vaccine based on an adenoviral vector (ChAdOxl nCov-19) that comprises a nucleic acid encoding amino acids 2-1273 of SARS-CoV-2 spike protein, i.e. including both SI and S2 subunits. One mode of carrying out the present invention would be to replace the spike sequence used by Doremalen by a shorter sequence comprising S2 epitopes only, e.g. amino acids 662-1273, or fragment thereof, like SEQ ID NO.: 2.
A different way of carrying out the present invention is the production of an RNA-based vaccine as described in Mulligan et al. Nature 2020, https://doi.org/10.1038/s41586-02Q- 2639-4, or Jackson et al., New Engl J Med 2020, DOI: 10.1056/NEJMoa2022483, but replacing the full-length spike protein sequences, or the RBD domain sequences disclosed in these publications, by a sequence comprising S2 epitopes only, like SEQ ID NO.: 2, or fragment thereof.
EXAMPLES
METHODS
Study design and participants
Human volunteers aged between 20 and 63 years participated in the study. The study was performed as a two-group testing program according to COVID- 19 status: (i) known and recovered from COVID-19 and (ii) unknown COVID-19 history. This design enabled comparison of test results between a group known to have had COVID- 19 (COVID- 19 known positive [COVID- 19kp]) and a group with unknown history, but potentially infected unknowingly in the past or recently (COVID19uk). Testing schedule and subsequent actions were determined by participants’ status, which included not infected, acutely ill/infectious, or recovered/immune (Supplementary Figure SI and Table SI). Four regular visits were scheduled at approximately 2-week intervals (see Supplementary Appendix).
Baseline and disease characteristics
A comprehensive assessment of participants’ baseline and disease characteristics including medication use and influenza vaccination was performed.
Testing materials
All test kits were CE-marked and commercially available.
For detection of SARS-CoV-2 RNA by RT-PCR, a throat swab was collected by qualified healthcare personnel. Samples were assayed using the Kylt® SARS-CoV-2 Initial Screening/Confirmation (AniCon Labor GmbH, Holtinghausen, Germany). Confirmatory RT-PCR
for positive initial RT-PCR results and IgM- (LFA) and IgA- (ELISA) positive participants were performed by an independent laboratory.
LFAs for IgM and IgG determination were used using fingertip blood or venous blood samples. The following test systems were evaluated: VivaDiag COVID-19 IgM/IgG Rapid Test (VivaChek Biotech Co Ltd, Hangzhou, China); 2019-nCoV IgG/IgM Rapid Test Cassette (MoLab GmbH, Langenfeld, Germany); SARS-CoV-2 rapid IgM/IgG antibody test (Nano Repro AG, Marburg, Germany); and PerGrande SARS-CoV-2 Antibody Detection Kit IgG (PerGrande BioTech Development Co Ltd, Beijing, China); all directed against the N protein of the virus.
Laboratory assays for specific SARS-CoV-2 IgA, IgG and total IgE (unspecific) were conducted using venous blood samples (IgG S 1/2: LIAISON SARS-CoV-2 S1/S2 IgG chemiluminescence immunoassay [CLIA; DiaSorin, Saluggia, Italy]; IgG SI: Anti-SARS-CoV-2 ELISA SI IgG [Euroimmun AG, Lubeck, Germany]; IgA (SI): anti-SARS-CoV-2 ELISA IgA [Euroimmun AG]; total IgE: Roche Elecsys Total IgE II assay [Roche Diagnostics, Rotkreuz, Switzerland]). All laboratory assays outlined above allow a quantitative readout. This feature was used to capture the temporal evolution of the antibody levels.
Digital self-monitoring
For real-time digital self-monitoring, participants were asked to record vital signs (body temperature and pulse) and any suspicious symptoms for COVID-19 daily.
Statistical analysis
Test results and demographic data were analyzed using descriptive statistics. Standard statistical parameters of the test performance, like sensitivity, specificity and positive and negative predictive values, were calculated. To that end, medical judgment and a post hoc classification of each participant’s Covid- 19 history — based on the full diagnostic information package accumulated during the testing program — was considered as gold standard. The (semi-)quantitative outcomes from the laboratory assay tests were plotted over time and evaluated by linear regression to quantify the dynamics of potential seroconversion.
RESULTS
Participants and baseline characteristics
Baseline demographics and characteristics are shown in Table 1. In total, 141 participants aged between 20 and 63 years entered the program (61 female); amongst these, 20 participants were known positives for COVID-19 (COVID-19kp; confirmed by RT-PCR and clinical assessment). There were no incident infections during the testing phase. During the program, 10 participants (8.3%) out of the 121 COVID-19uk participants were medically judged to have had COVID-19 prior to testing, based on diagnostic results, evidence for risk of infection and medical history, indicating a mild course of infection with only minor clinical symptoms; this subset was subsequently denoted as COVID-19-identified-positive (COVID-19ip). Of these, nine participants were only positive by DiaSorin S1/S2 IgG CLIA and one participant was positive by IgA/IgG SI ELISA at Visit 1. The remaining 111 participants from the COVID- 19uk cohort were re-classified as CO VID-19 negative (COVID-19neg; Table 1 and Supplementary Figure S2). Participants from the COVID- 19kp or COVID-lOip groups were numerically less likely to report allergies compared with the COVID- 19neg group, including the most commonly reported allergy ‘allergic rhinitis due to pollen’, less likely to take antihistamines, to have baseline IgE values of >100 lU/mL and less likely to have had an influenza vaccination in 2019/2020 (Table 1 and Supplementary Figure S3).
'Reported by at least 10 participants in any group. Detection of SARS-CoV-2 antibodies by LFA
Amongst COVID-19kp participants, the frequency of positive LFA IgG and IgM testing results generally decreased over time, except for the MoLab 2019-nCoV IgM LFA. In COVID-19ip participants, the frequency of positive LFA results (IgM and IgG) was much lower compared with COVID-19kp participants (0-10.8% vs. 33.8-75.7%, respectively).
Positive IgM results in the absence of additional indication of SARS-CoV-2 infection were found in 10 (8.3%) COVID-19neg participants, using at least one LFA and at least once over the observation period. In most cases, participants had an allergic disposition with symptoms of seasonal allergic reactions and/or potential infections during testing, with subacute symptoms (such as pain or increased body temperature). None of the participants were RT- PCR positive and no
other SARS-CoV-2 antibodies were observed at any visit. It is therefore likely that these isolated IgM results were unspecific and probably caused by infection other than SARS-CoV-2.
Detection of SARS-CoV-2 antibodies by laboratory serology
A pronounced decline in S 1 IgA (Euroimmun) levels was observed over time, in particular amongst COVID-19kp participants (Figure 2A). In comparison, the overall assay levels of the COVID- 19ip group (Figure 2B) fell clearly below the COVID- 19kp group, with levels that were hardly sufficient to generate a positive test signal (Figure 2B).
A similar decline in levels was observed for the SI -specific IgG response (Euroimmun) in the COVID- 19kp group (Figure 3A). As observed with IgA, the overall assay levels of the COVID- 19ip group fell clearly below the “known positive” level (Figure 3B), and were therefore not sufficient to generate a positive test signal (Figure 3C).
In contrast to the Euroimmun ELISAs, the Diasorin CLIA, which detects IgG against both S 1 and S2, showed a sustained IgG response over time (Figure 4A) in the COVID-19kp group. In the COVID- 19ip group (Figure 4B), the observed immune response against S1/S2 remained stable and persistent, although notably below the COVID- 19kp group; however, the signal remained sufficiently large for a positive detection (Figure 4C).
Claims
1. Pharmacologically active compound which either elicits an immune response against the S2 subunit of SARS-CoV-2 spike protein or neutralizes a biological activity of the S2 subunit of SARS-CoV-2 spike protein for use in the prophylaxis or treatment of COVID-19.
2. Neutralizing antibody which is specific for SARS-CoV-2 spike protein S2 subunit, but does not bind to the SI subunit, for use in the prophylaxis or treatment of COVID-19.
3. Vaccine against SARS-CoV-2 infection and COVID-19, comprising one or more antigenic peptides of spike protein S2 subunit, or a nucleic acid sequence coding for one or more antigenic peptides of spike protein S2 subunit, but no peptides of spike protein SI subunit, or respective nucleic acid sequence.
4. Vaccine against SARS-CoV-2 infection and COVID-19, comprising one or more antigenic peptides of spike protein S2 subunit, or a nucleic acid sequence coding for one or more antigenic peptides of spike protein S2 subunit, and peptides of spike protein SI subunit, or respective nucleic acid sequence.
5. Diagnostic kit for the determination of the level of antibodies specific for SARS-CoV-2 spike protein S2 subunit in a sample, comprising a. isolated SARS-CoV-2 S2 subunit antigen, or fragment thereof b. means for detection whether antibodies from that sample have bound to said S2 subunit antigen.
6. Process for deciding on a therapeutic intervention for a patient suspected or known to be infected by SARS-CoV-2, with the steps a. Obtaining an either blood sample, or a saliva sample or a tear fluid sample from said patient; b. Determining the level of antibodies against spike protein SI subunit and the level of antibodies against spike protein S2 subunit in said sample; and
c. Deciding on the therapeutic intervention based on the results obtained in step b. Method of prophylactic or therapeutic treatment of an individual being at risk of developing COVID-19, or having clinical signs of COVID-19, or having been tested positive for SARS-CoV-2 in a diagnostic test, comprising administering to the individual a therapeutically effective amount of a compound which either elicits an immune response against the S2 subunit of SARS-CoV-2 spike protein, or neutralizes a biological activity of the S2 subunit of SARS-CoV-2 spike protein.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20201788.5 | 2020-10-14 | ||
EP20201788 | 2020-10-14 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2022079001A2 true WO2022079001A2 (en) | 2022-04-21 |
WO2022079001A3 WO2022079001A3 (en) | 2022-05-27 |
Family
ID=72885423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2021/078138 WO2022079001A2 (en) | 2020-10-14 | 2021-10-12 | Sars-cov-2 antigens, diagnostic and therapeutic uses |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022079001A2 (en) |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111560054A (en) * | 2020-06-16 | 2020-08-21 | 哈尔滨吉象隆生物技术有限公司 | Polypeptide for inhibiting novel coronavirus infection and screening method thereof |
-
2021
- 2021-10-12 WO PCT/EP2021/078138 patent/WO2022079001A2/en active Application Filing
Non-Patent Citations (33)
Title |
---|
"GenBank", Database accession no. MN908947 |
"NCBI", Database accession no. YP 009724390 |
AHMED ET AL., VIRUSES, vol. 12, 2020, pages 254 |
BHATTACHARYA, J MED VIROL, vol. 92, 2020, pages 618 - 631 |
CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917 |
DARLING, R.J.BRAULT P-A.: "Kinetic exclusion assay technology: Characterization of Molecular Interactions", ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, vol. 2, no. 6, December 2004 (2004-12-01), pages 647 - 657, XP055396049, DOI: 10.1089/adt.2004.2.647 |
DOREMALEN ET AL., BIORXIV 2020.05.13.093195 |
E.A. KABATT.T. WUH. BILOFSKYM. REID-MILLERH. PERRY: "Sequence of Proteins of Immunological Interest", 1983, NATIONAL INSTITUTES OF HEALTH |
ELSHABRAWY ET AL., PLOS ONE, vol. 7, no. 11, 2010, pages e50366 |
ELSHABRAWY, VACCINES, vol. 8, 2020, pages 335 |
GUO ET AL., FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, vol. 8, 2020, pages 410 |
HO M, ANTIBODY THER, vol. 3, no. 2, 2020, pages 109 - 114 |
JACKSON ET AL., NEW ENGL J MED, 2020 |
JIANG ET AL., TRENDS IMMUNOL, vol. 41, no. 5, 2020, pages 355 - 359 |
KALITA ET AL., MICROBIAL PATHOGENESIS, vol. 145, 2020, pages 10236 |
LEE CY ET AL., FRONT. IMMUNOL., vol. 11, 2020, pages 879 |
LIP ET AL., J VIROL, vol. 80, no. 2, 2006, pages 841 - 950 |
LIP ET AL., J VIROL., vol. 80, no. 2, 2006, pages 841 - 950 |
LV ET AL., CELL REPORTS, vol. 31, no. 9, 2020, pages 1 - 6 |
MALMQVIST M.: "Surface plasmon resonance for detection and measurement of antibody-antigen affinity and kinetics", CURR OPIN IMMUNOL, vol. 5, no. 2, April 1993 (1993-04-01), pages 282 - 6, XP023942016, DOI: 10.1016/0952-7915(93)90019-O |
MULLIGAN ET AL., MEDRXIV 2020.06.30.20142570 |
MULLIGAN ET AL., NATURE, vol. 581, 2020, pages 215 - 220, Retrieved from the Internet <URL:https://doi.org/10.1038/s41586-020-2639-4> |
NISREEN MAO ET AL., EID JOURNAL, vol. 26, no. 7, 2020, pages 1478 - 1488 |
PEROTTA ET AL., RESPIRATORY MEDICINE, vol. 168, 2020, pages 105996 |
ROGERS ET AL., SCIENCE, 2020 |
SALVATORI ET AL., J TRANSL MED, vol. 18, 2020, pages 222 |
SMITH ET AL., NATURE COMM, vol. 11, 2020, pages 2601 |
SU ET AL., VACCINE, vol. 38, 2020, pages 5071 - 5075 |
WALLS ET AL., CELL, vol. 180, 2020, pages 281 - 292 |
WANG ET AL., MED SCI MONIT, vol. 26, 2020, pages e924700 |
WANG ET AL., NATURE COMMUNICATIONS, vol. 11, 2020, pages 2251 |
ZHENG ET AL., EUROSURVEILLANCE, vol. 25, no. 28, 2020, pages 19 - 28 |
ZHU ET AL., LANCET, vol. 395, 2020, pages 1845 - 1854 |
Also Published As
Publication number | Publication date |
---|---|
WO2022079001A3 (en) | 2022-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6323718B2 (en) | Antibodies that detoxify human immunodeficiency virus and methods of use thereof. | |
US11993644B2 (en) | Antigen binding molecules targeting SARS-CoV-2 | |
JP7463366B2 (en) | Novel anti-Zika virus antibodies and uses thereof | |
US10981977B2 (en) | Anti-HERV-K envelope protein antibodies and methods for detecting HERV-K envelope protein in patients with sporadic amyotrophic lateral sclerosis | |
US20210277093A1 (en) | Immunotherapeutic compositions and methods of production for coronavirus | |
JP2017510627A (en) | Combined treatment of multiple sclerosis | |
EP4157867A1 (en) | Human recombinant monoclonal antibody against sars-cov-2 spike glycoprotein | |
JP2024518335A (en) | Human neutralizing monoclonal antibodies against SARS-CoV-2 and their uses | |
WO2022065445A1 (en) | SARS-CoV-2 NEUTRALIZING ANTIBODY OR FRAGMENT THEREOF | |
JP2023522208A (en) | Methods of treating complement-mediated disorders caused by viruses | |
US20230250157A1 (en) | Antibodies for coronavirus and uses thereof | |
WO2022079001A2 (en) | Sars-cov-2 antigens, diagnostic and therapeutic uses | |
US20160200799A1 (en) | Anti-influenza virus neutralizing antibody | |
KR20220002427A (en) | Compositions comprising anti-RSV antibodies and dosing regimens thereof | |
US20240043506A1 (en) | Sars-cov-2 antibodies | |
CN111153990B (en) | Monoclonal antibody aiming at Echo30, preparation method and application thereof | |
US20240285753A1 (en) | Epitope-scaffold immunogens for pancoronavirus vaccines | |
JP2024044204A (en) | ANTI-SARS-CoV-2 ANTIBODY | |
AU2023232815A1 (en) | Hmpv antibodies and their use | |
WO2024138141A2 (en) | Antibodies against metapneumovirus fusion (f) protein and uses thereof | |
Van Dang | Viral Proteins as Targets for Antibody Therapeutics and Molecular Detection Agents | |
AU2022361501A1 (en) | Anti-sars-cov-2 antibodies and uses thereof i | |
CN115850454A (en) | Anti-coxsackievirus A16 antibody and preparation method and application thereof | |
KR20220122467A (en) | Antibody against SARS-coronavirus-2 and the uses thereof | |
JP2024014723A (en) | ANTIBODY AGAINST SARS-CoV-2 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21789758 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21789758 Country of ref document: EP Kind code of ref document: A2 |